GlassScriptPhysician profile
Aaron J Feingold
NPI 1811947328
$3,108.83
in general payments reported to CMS, 2019-2025
31 companies · $636 in 2025
The $636 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2020: $134 · 2021: $127 · 2022: $377 · 2023: $385 · 2024: $1,140 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,160.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $390.97 | 2019-2024 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, Watchman |
| Heartflow, INC. | $359.49 | 2024-2025 | |
| Cvrx, INC. | $310.74 | 2024-2025 | Barostim Neo System |
| Novo Nordisk INC | $308.13 | 2019-2025 | Wegovy, Ozempic |
| Impulse Dynamics (USA) INC. | $245.86 | 2021-2024 | Optimizer |
| Novartis Pharmaceuticals Corporation | $156.50 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $150.50 | 2019-2025 | Camzyos |
| Abbott Laboratories | $147.30 | 2019-2024 | Accent, Cardiomems, Merlin@Home |
| Pfizer INC. | $115.83 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.85 | 2019-2024 | Jardiance |
| Atricure, INC. | $97.91 | 2024-2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Amgen INC. | $87.95 | 2019-2025 | Repatha |
| Sanofi-Aventis U.S. LLC | $70.26 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $68.98 | 2019-2022 | |
| Abiomed | $64.91 | 2024-2025 | Impella |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $52.21 | 2025 | Indigo System |
| Alnylam Pharmaceuticals INC. | $51.22 | 2023-2025 | Onpattro |
| Daiichi Sankyo INC. | $46.02 | 2022-2024 | Injectafer |
| Biosense Webster, INC. | $30.20 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $29.76 | 2023 | Lifevest |
| Esperion Therapeutics, INC. | $28.90 | 2023 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $27.60 | 2022-2023 | |
| Medtronic, INC. | $27.38 | 2025 | Ffrangio |
| Gilead Sciences, INC. | $24.15 | 2019 | |
| Kestra Medical Technology Services, INC. | $19.73 | 2024 | Assure Wcd |
| Edwards Lifesciences Corporation | $18.72 | 2019 | |
| Medtronic Vascular, INC. | $18.53 | 2020 | |
| Azurity Pharmaceuticals, INC. | $14.55 | 2024 | Edarbyclor |
| Sanofi Pasteur INC. | $14.29 | 2020 | |
| Itamar Medical INC | $14.18 | 2024 | Watchpatone |
| Astrazeneca Pharmaceuticals LP | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Feingold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.